Logo
x

Search

Subscribe Now

sickle cell disease

Novartis's Adakveo (crizanlizumab) Receives NICE Recommendation as a New Therapy for Sickle Cell Disease

Novartis's Adakveo (crizanlizumab) Receives NICE Recommendation as a New Therapy for Sickle Cell Disease

  • October 6, 2021
Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT for $353M

Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT for $353M

  • March 17, 2021
Novartis Collaborates with Bill & Melinda Gates Foundation to Discover and Develop Gene Therapy for Sickle Cell Disease

Novartis Collaborates with Bill & Melinda Gates Foundation to Discover and Develop Gene Therapy for Sickle Cell Disease

  • February 18, 2021
Global Blood's Oxbryta (Voxelotor) Receives the US FDA's Accelerated Approval for Treatment of Sickle Cell Disease

Global Blood's Oxbryta (Voxelotor) Receives the US FDA's Accelerated Approval for Treatment of Sickle Cell Disease

  • November 25, 2019
Novartis' Adakveo (crizanlizumab) Receives the US FDA's Approval for Reducing the Frequency of VOCs in Sickle Cell Disease

Novartis' Adakveo (crizanlizumab) Receives the US FDA's Approval for Reducing the Frequency of VOCs in Sickle Cell Disease

  • November 18, 2019
Pfizer Reports Results of Rivipansel in P-III RESET Study for Sickle Cell Disease with Vaso-Occlusive Crisis

Pfizer Reports Results of Rivipansel in P-III RESET Study for Sickle Cell Disease with Vaso-Occlusive Crisis

  • August 5, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.